Abstract. We previously found apolipoprotein (apoE) 4-dependent lower metabolic activity in nucleus basalis of Meynert (NBM) neurons in Alzheimer disease (AD). In the present study we examined the metabolic activity in the NBM of 39 mentally intact control subjects with different APOE genotype. The control subjects had either no AD pathology (Braak stage 0) or the very beginning of AD pathology (Braak stage I-II). We used the Golgi apparatus (GA) size as a measure of neuronal metabolic activity. Control subjects carrying an apoE 4 allele showed reduced neuronal metabolism; they had significantly more neurons with smaller GA sizes compared to control subjects not carrying an apoE 4 allele. Only control subjects not carrying an apoE 4 allele had increased neuronal metabolism in Braak I-II subjects. They had more neurons with larger GA sizes compared to Braak 0 subjects, which may reflect a compensatory mechanism. Our data indicate that APOE 4 may act by a lower neuronal metabolism as a risk factor for cognitive impairment in normal aging and early prodromal AD. As the disease progresses into later stages of AD (Braak V-VI) neuronal metabolism strongly diminishes, resulting in neurons with extremely small GA sizes, irrespective of APOE genotype.
INTRODUCTION
The cholinergic system is strongly affected in Alzheimer disease (AD) (1) . Changes reported are decreased acetyl-cholinesterase activity in the cerebral cortex and decreased choline acetyltransferase (ChAT) activity in the amygdala, hippocampus, and cortex (2), reduced ChAT activity and acetyl-cholinesterase-positive fibers in the frontal, parietal, temporal, and visual cortices (3), and a below normal level of expression of ChAT mRNA per cell in the nucleus basalis of Meynert (NBM) (4) . In the subcortical cholinergic basal forebrain region (Ch4 area according to Mesulam et al [5] ) of rhesus monkeys with age-related cognitive decline, Smith et al (6) demonstrated a loss of neurotrophin receptor p75 in 43% of the cholinergic neurons, with parallel reductions in ChAT. Delivery of nerve growth factor to the region of the cholinergic somata restored the number of immunolabeled neurons to within 8% of the values observed in young animals.
We hypothesize that decreased neuronal metabolism is a major hallmark of degeneration in AD (7) and that high or enhanced metabolism would protect neurons against degenerative changes in aging and AD, a phenomenon we paraphrased as ''use it or lose it'' (8) . The size changes of the Golgi apparatus (GA) were used as a measure for alterations in neuronal metabolism. The functioning of the GA is an important part of metabolism: newly synthesized proteins destined for fast axonal transport (e.g. membrane associated proteins) are routed through the neuronal soma, as are proteins targeted for membrane insertion or secretion in non-neuronal cells, and passing through the GA is an obligatory step in this process (9) .
Previously, we have demonstrated smaller GA sizes in cholinergic NBM neurons of AD patients compared to controls, suggesting a lower metabolism (10) . In addition we found that AD patients carrying an apoE 4 allele had an extra diminishment in the size of the GA, suggesting a decreased metabolism because of apoE 4 (11) . APOE polymorphism on chromosome 19 is a major risk factor for sporadic AD (12, 13) . The inheritance of 1 or 2 apoE 4 alleles increases the risk of getting AD, reduces the age of onset of the disease (12), decreases performance of AD patients in cognitive tests (14) , and may explain up to 17% of the prevalence of AD in the general population (15) . We hypothesized that the presence of apoE 4 reduces neuronal metabolism and thereby makes the neurons more vulnerable to the process of aging and AD (11) . An alternative hypothesis would be that neuronal metabolism in the NBM would decrease more in AD patients with an apoE 4 allele, during the course of the AD process. In order to distinguish between these 2 possibilities we examined in the present study whether the apoE 4 genotype is already accompanied by a lower neuronal metabolism in aged, mentally unaffected control subjects ranging from Braak stage 0 to Braak stage II (16) . * Statistically significant differences (Mann-Whitney U Test) between control subjects and AD patients; ** Statistically significant differences (Mann-Whitney U Test) between the AD patients with no ⑀4 allele, with 1 ⑀4 allele, and with 2 ⑀4 alleles. For p values, see Results and Table 3) . Abbreviations: BW, brain weight; CSF, cerebrospinal fluid; Fix, fixation time; PMD, postmortem delay. Braak stages according to Braak and Braak (16) .
MATERIALS AND METHODS

Tissue Collection
Brains from 39 control subjects and 16 AD patients were studied. Written informed consent for brain autopsy and the use of tissue and medical records for research purposes was obtained as part of the program of the Netherlands Brain Bank. The pH of the cerebrospinal fluid (CSF) was measured as indicator of agonal state ( [17] ; Table 1 ). Tissue blocks containing the hypothalamus and the NBM were dissected and fixed in 4% formaldehyde in phosphate-buffered saline (PBS; pH 7.6) at room temperature (RT), for about 1 month. The fixed tissue blocks were dehydrated in graded ethanol, embedded in paraffin, and cut serially in 6-m coronal sections. For anatomical orientation, every fiftieth section was mounted on chrome-aluminium-sulphate-coated glass slides, deparaffinized, hydrated, and stained with 0.5% thionine. APOE genotyping was performed on frozen tissue (18) .
Clinico-Pathological Diagnosis
The medical records of all control cases and AD patients were carefully evaluated. Excluded were all controls with any neurological disorder that involved cognitive functions and subjects with a medical history of opioids, corticosteroids, or antidepressants for more than 1 week prior to death or in the terminal phase. AD patients were diagnosed as ''probable AD'' by excluding other possible causes of dementia by history, physical examination, and laboratory tests according to the NINCDS-ADRDA criteria (19) . The severity of dementia was evaluated by means of the global deterioration scale ( [20] ; Table 2). The clinical diagnosis ''non-demented control'' and ''probable AD'' was confirmed by a systematic neuropathological study (21) . Pathological alterations of the control subjects and AD patients were categorized according to Braak's score ( [16] ; Tables 1, 2 ). Neurofibrillary tangles and neuropil threads permit the differentiation of 6 stages of which the first 2 stages are characterized by an either mild or severe alteration of the transentorhinal layer pre-alpha (trans-entorhinal stages I-II). From the control subjects we excluded patients that had more neuropathological abnormalities than Braak stage II. In late AD (stages V-VI) virtually all isocortical association areas are affected (16) .
Immunocytochemistry
To visualize the GA we used the polyclonal antibody HG-130 (for specificity tests see [22] ) raised against an 18 amino acids epitope of a sialoglycoprotein MG-160 of the medial cisternae of the human GA (23) .
All staining procedures were performed at RT except where indicated differently. Between each step the sections were rinsed in Tris-buffered saline (TBS; 0.05 M Tris and 0.15 M NaCl, pH 7.6). The sections were first deparaffinized in xylene for 20 min, rehydrated in graded ethanol and distilled water, and then exposed to microwave treatment for antigen retrieval (24) in 1% ZnSO 4 . The sections underwent a 5-min microwave heating with a minimum temperature of 90ЊC and a maximum temperature of 95ЊC, followed by 1 min without microwave heating during which the position of the jar was changed, followed by 5 min microwave heating to a maximum of 95ЊC. The sections were cooled for 20 min at RT and incubated in a TBS/ 5% defatted milk-solution (Campina, Eindhoven, The Netherlands) for 1 hour and incubated with TBS/10% horse plasma for 10 min to reduce background staining. Subsequently, the sections were incubated with the primary antibody ␣-HG-130 diluted 1:1000 in PBS (pH 7.6) for 1 hour and 15 min at RT, followed by 16 hours incubation at 4ЊC. The next day, the sections were incubated with goat-anti-rabbit serum at a dilution of 1:100 in TBS for 1 hour. The sections were subsequently incubated with peroxidase-anti-peroxidase at a dilution of 1: 2.2 mg/ml TBS and 0.03% H 2 O 2 for 30 min. Finally, the sections were dehydrated in graded ethanol series and xylene and cover slipped with Entellan (Merck, Darmstadt, Germany).
For the ChAT staining the sections were deparaffinized and treated with the same microwave procedure as for the HG-130 staining. The sections were incubated in a TBS/5% normal donkey serum/0.3% Triton/5% defatted milk solution (pH 7.6) for 30 min to reduce background staining. Subsequently the sections were incubated with the primary antibody ␣-ChAT (Chemicon, Temecula, CA) diluted 1:50 in a TBS/5% normal donkey serum/0.3% Triton solution (pH 7.6) for 72 hours incubation at 4ЊC. Next, the sections were incubated with biotinylated anti-goat IgG, affinity-purified, made in horse (Vector, Burlingame, CA) at a dilution of 1:400 in TBS/2% BSA for 1 hour. The staining was visualized using the same procedure as for the HG-130 staining.
Morphometry of the Nucleus Basalis of Meynert
As the NBM is a very extensive cell system, measurements were performed in a standardized part of the NBM, i.e. the medial and lateral subdivisions of the anterior part; Ch4-am and Ch4-al according to Mesulam et al (25) . Only those sections were selected that contained the Ch4a, the fornix, and/or the anterior commissure (Fig. 1A, B) .
Image Analysis
Measurements of the GA area were performed using an IBAS-KAT (Kontron KAT based system) image analysis system (10) . The image analysis system was connected to a SONY black and white CCD camera mounted on a Zeiss Axioskop microscope. All measurements were performed using a 560-nm small band DEPAL filter (Scott, Mainz, Germany) in the illumination pathway. Using the ϫ 2.5 objective, an image covering the entire NBM in each section was loaded into the IBAS and displayed on the computer monitor. The X-Y scanning stage coordinates of the position of this image in the section were stored and the contours of the NBM were manually outlined (Fig. 1B) . For sampling, this image was covered by a grid covering area that would be ''seen by the camera,'' using a ϫ 40 objective. From this grid, 40% of the fields covering the NBM outline was selected in a systematic random way. stored scanning stage position of the entire image, scanning stage coordinates were calculated to put the selected fields in view when looking through an ϫ 40 objective. For these calculations the deviations of the optical axis between the objectives were also taken into account. Next, the ϫ 40 objective was positioned in front and the images at the selected positions were automatically loaded and stored. As the first step to calculate the GA area in individual cell profiles in each of these high magnification images, an automatic segmentation of the GA staining was done, resulting in a binary ''Golgi mask'' image. Subsequently, all neuron profiles containing a nucleolus were outlined manually regardless of the size of the GA or the visibility of the GA. From each of these neuron outlines the area covered by the Golgi mask and the total profile area was determined. Three stained sections per subject were analyzed, resulting in GA areas of 80 NBM neurons per subject.
Statistical Analysis
The size of the GA revealed a large variance within each patient, obscuring differences between patients. Therefore, the data were pooled in frequency distribution histograms (Fig. 3A-I) . Normality of the distributions of the GA area measurements was tested using the Lilliefors test (26) . The test illustrated that none of the distributions were normal. Differences between the distributions were tested using the non-parametric KolmogorovSmirnov two-sample test. The Kolmogorov-Smirnov test examines differences in both shape (dispersion and skewing) and location of the distributions and is thus more comprehensive than alternative non-parametric tests.
Age, brain weight, fixation time, pH of CSF, and postmortem delay of the different groups were tested with the Mann-Whitney U-test (Table 3 ). The possible effects of these parameters on GA size were checked using multiple regression. The results of the presently used new antibody (HG-130) and the previously used antibody (MG-160) were compared using Spearman's correlation coefficient and non-parametric linear regression.
RESULTS
Immunocytochemical Staining
A clear staining of the GA in the NBM neurons was obtained, displaying the characteristic granular cytoplasmic pattern with a preferential perinuclear distribution ( Fig. 2A-H) . Differences in the size of the GA profiles were most noticeable for control subjects ( Fig. 2A-F ) compared to AD patients (Fig. 2G, H) . More GA size differences are visible; control subjects without AD pathology (Braak stage 0; Fig. 2A, B) versus control subjects with Braak stage I or II (Fig. 2C-F) ; and subjects without ( Fig. 2A, C , E, G) or with (Fig. 2B, D, F, H) an apoE 4 allele.
Matching of Age, Fixation Time, Postmortem Delay, Brain Weight, and pH of CSF Parameters
There were no differences in age and fixation time parameters between any of the studied (sub-)groups (Table 165 166 3). The postmortem delay and brain weight parameters were significantly different between the control subjects and the AD patients. The postmortem delay was significantly lower in the AD patients not carrying an 4 allele compared to the AD patients carrying 1 or 2 apoE 4 alleles. Moreover, the postmortem delay in the group of AD patients without an apoE 4 allele tended to be lower than that of the AD patients carrying 1 apoE 4 allele and that of the AD patients carrying 2 apoE 4 alleles. The pH of CSF was lower in the AD patients carrying 1 apoE 4 allele than in those carrying 2 apoE 4 alleles. However, multiple regression of all parameters on GA size in the controls and AD patients with different APOE genotypes did not show a significant correlation (age, p ϭ 0.985; sex, p ϭ 0.962; fixation time, p ϭ 0.970; brain weight, p ϭ 0.886; pH, p ϭ 0.991; postmortem delay, p ϭ 0.866), so that the differences in the values of these parameters did not significantly affect the outcomes. Figure 3 shows the frequency distributions. We found that controls (Braak 0-II) carrying an apoE 4 allele revealed more neurons with smaller GA sizes (Fig. 3A) than controls not carrying an apoE 4 allele. Controls carrying an apoE 4 allele with the first signs of AD (Braak stage I-II) and those without AD pathology (Braak stage 0) had the same distribution of GA sizes (Fig. 3E) . Controls not having AD pathology (Braak stage 0) but carrying an apoE 4 allele had more neurons with smaller GA sizes than Braak stage 0 controls without an apoE 4 allele (Fig. 3B) . Controls having early AD pathology (Braak stage I-II) and carrying an apoE 4 allele had more neurons with smaller GA sizes than controls (Braak stage I-II) without an apoE 4 allele (Braak stage 0; Fig. 3C ). Furthermore, of the controls not carrying an apoE 4 allele, those subjects with starting AD pathology (Braak stage I-II) revealed more neurons with an average GA size (Fig. 3D) .
Golgi Apparatus in the NBM of Control Subjects
Golgi Apparatus in the NBM of Alzheimer Patients
The AD patients used here were also used in a previous study (11) . The staining pattern of the MG-160 antibody used earlier related to the HG-130 antibody used in this study in these 16 AD patients correlated significantly (r ϭ 0.755, p Ͻ 0.001). The linear regression coefficient was 1.24 and not significantly different from 1.0 (p ഠ 0.4), indicating that the 2 antibodies have similar staining characteristics. Figure 3 shows the frequency distributions. Irrespective of their APOE genotype, AD patients had more neurons with smaller GA sizes and more neurons with larger GA sizes as compared to control subjects who had more neurons with average GA sizes (Fig. 3F-H) . AD patients carrying an apoE used 4 allele had many more neurons with extremely small GA sizes than the non-carriers (Fig.   3I ). AD patients with 1 or 2 apoE 4 alleles had significantly more neurons with smaller GA sizes than AD patients without an apoE 4 allele (p Ͻ 0.001 in both groups). The GA size of AD patients with 1 apoE 4 allele and with 2 apoE 4 alleles were not different (p ϭ 0.735).
Golgi Apparatus and Cell Profile Area
Comparing control subjects with an apoE 4 allele (Braak 0-II) to those without an apoE 4 allele (Braak 0-II) showed that the GA size was significantly smaller in subjects with an apoE 4 allele ( Fig. 3A ; p Ͻ 0.001), whereas the cell profile area was comparable (p ϭ 0.14). Moreover, comparing control subjects without AD pathology (Braak 0) to those that had starting AD pathology (Braak I-II), again, the GA size was significantly different (more neurons with an average GA size in Braak I-II subjects; p Ͻ 0.001), although cell profile area was equal (p ϭ 0.23).
DISCUSSION
The data from the present study fully support our hypothesis that apoE 4 may act as a risk factor for AD by decreasing neuronal metabolism, thus making neurons more vulnerable for factors related to aging (11, 27, 28) . Even in controls that did not have any sign of AD pathology (Braak stage 0) we observed a decrease in neuronal metabolism in those subjects carrying an apoE 4 allele. This illustrates that the decreased neuronal metabolism in control apoE 4 carriers is not due to a starting AD process. Statistical analysis showed that the smaller GA size was not related to a difference in cell profile area. Moreover, evidence was obtained for a further strong decrease of neuronal metabolism in the later course of the AD process (Braak stage V-VI) in all APOE genotypes. Of all AD patients, those carrying 1 or 2 apoE 4 alleles show the same distribution of GA sizes, pointing to a similar degree of metabolic reduction. These data confirm previous studies (10, 11) and fully agree with the observation that AD patients carrying 1 or 2 apoE 4 alleles also reveal a similar reduction in ChAT activity in the temporal cortex (29) .
AD Pathology and apoE 4 Affect Metabolism Independently in AD and Controls
Not only the degree of hypometabolism in AD but also the course of the disease seems to be influenced by the presence of an apoE 4 allele. The present study shows that controls carrying an apoE 4 allele showed fewer neurons with large GA sizes, irrespective of their Braak stage (Braak 0, I or II). Also, during the start of the AD process (Braak I-II), a significant increase in GA size was found compared to controls without AD pathology (Braak 0), both not carrying an apoE 4 allele. As Braak staging (0, I, or II) and APOE genotype (with or without an apoE 4 allele) were not correlated, the data indicate that APOE 4 genotype and the beginning of AD pathology (Braak stage I-II) are independently affecting neuronal metabolism in the NBM. This is in agreement with Mielke et al (30) , who observed that the severity of dementia and apoE 4 status are independent predictors of the cerebral metabolic glucose pattern.
Additionally, AD patients carrying an apoE 4 allele had significantly more neurons with smaller GA sizes compared to AD patients not carrying an apoE 4 allele, irrespective of their Braak stage. No difference was found between AD patients with Braak stage V and Braak stage VI, irrespective of their APOE genotype.
Reduced Metabolism, apoE 4, and Controls
The data of the present study suggest that cognitively normal controls carrying an apoE 4 allele have a lower metabolism in the NBM. More studies have reported lower metabolism in cognitively normal controls carrying an apoE 4 allele compared to non-carriers: Allen et al (31) found significantly reduced ChAT activity (70%) in the temporal cortex in controls with an apoE 4 allele. Small et al (32) observed in cognitively normal subjects at risk of AD and carrying an apoE 4 allele, significantly lower parietal and higher left-right parietal asymmetry in regional cerebral glucose metabolism. Reiman et al (33) showed, in addition to reductions in parietal regions, significantly reduced rates of regional cerebral glucose metabolism in posterior cingulate, temporal, and prefrontal regions, compared to subjects without an apoE 4 allele. A 2-year-interval period in cognitively normal subjects who were at risk for AD resulted in a regional cerebral glucose metabolic decline in the left posterior cingulate region and the inferior parietal and lateral temporal regions only in those subjects carrying an apoE 4 allele and not the non-carriers (34) . Cognitive function is also affected by the presence of 4, as Deary et al (35) found cognitive decline in controls carrying 1 or 2 apoE 4 alleles. No difference was seen in youth (age 11), but a significant impairment was found at the age of 80.
In addition to the inheritance of an apoE 4 allele, our data showed that the start of AD also changes metabolism. Interestingly, not only a reduction of neurons with large GA sizes was seen comparing Braak I-II to Braak 0, but also a subpopulation of neurons was found that showed larger GA sizes in subjects with Braak I-II. We suggest that this shift of small GA size to average GA sizes may be a metabolic compensation during the early AD process. In addition, this shift towards higher activity did not occur in 4 carriers. DeKosky et al (36) reported increased levels of ChAT in the superior frontal cortex and the hippocampus of subjects that are mild cognitively impaired and suggested that the cholinergic system is capable of compensatory responses during the early stage of dementia.
Hypometabolism in the Brain
The mechanism by which APOE 4 causes reduced neuronal metabolism needs further investigation. Especially, the way in which it presents a risk factor for cognitive impairment in normal aging and its effects in a long prodromal AD trajectory (37) . Reduction in brain glucose may be an aggravating, if not a causal factor, in the pathogenesis of AD (38) as indicated by model studies for neurofibrillary tangle formation. Neurofibrillary tangles are the first histopathological hallmarks appearing in AD (39) . Ghebremedhin et al (40) demonstrated an association between the apoE 4 allele with the earliest stage of NFT AD pathology (Braak I) in the asymptomatic phase of AD in very young subjects, with a mean age of 38 years. The fact that reduced cerebral glucose metabolism was also found in controls at risk for AD carrying an apoE 4 allele (32, 33) along with our finding that the NBM has a reduced metabolism in controls carrying an apoE 4 allele indicates that a reduction in metabolism may be one of the earliest steps in the Alzheimer process.
